Abingworth raises $465m for new life sciences fund Abingworth Bioventures 8
Oversubscribed transatlantic fund to invest in US, UK and European life science companies developing innovative therapeutics with potential to significantly improve human health
News provided by
Share this article
Share this article
LONDON, Feb. 3, 2021 /PRNewswire/ Abingworth, a leading international life sciences investment group, today announced the final closing of its latest transatlantic venture fund, Abingworth Bioventures 8 (ABV 8) at $465 million. ABV 8, which is Abingworth s 13
th life sciences fund, exceeded its target of $375 million and closed at its hard cap.
ABV 8 will target companies developing innovative therapeutics with potential to significantly improve human health. As with previous funds, ABV 8 will invest in opportunities in the US, UK and Continental Europe.